Viking Therapeutics Inc. has announced upcoming presentations related to its VK2735 obesity program at major medical conferences in 2025. At ObesityWeek® 2025, being held from November 4-7 in Atlanta, the company will present results from an exploratory analysis of the Phase 2 VENTURE clinical trial, which evaluated 13 weeks of weekly subcutaneous VK2735 treatment in obese subjects, focusing on its impact on prediabetes and metabolic syndrome. Additionally, Viking will present the design of its ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with overweight or obesity and at least one weight-related co-morbid condition. The company will also make two presentations at the American Heart Association Scientific Sessions 2025 in New Orleans from November 7-10. These will include the design of the ongoing Phase 3 VANQUISH-2 study of subcutaneous VK2735 in Type 2 diabetes patients with obesity or overweight, and results of an analysis on the prevalence of cardiometabolic conditions across different body mass index categories. All presentations are scheduled for future dates.